Table 1 Demographic characteristics and clinical information of OMICRON asymptomatic infected patients
Study group (n) | Gender (M/F) | Age (years) | Presence or absence of chronic underlying disease (yes/no) | First NLR | Length of stay (days) | Outcome (death/survival) | Duration of infection (days) | Blood sampling period |
|---|---|---|---|---|---|---|---|---|
CD3CD4 + T lymphocyte-reduced group (n = 138) | 85/53 | 17.67 ± 13.18 | No | 4.65 ± 4 | 16.83 ± 7.26 | Survival | 14.83 ± 7.26 | April 1–April 14, 2022 |
Control group (n = 143) | 82/61 | 25.63 ± 12.66 | No | 1.61 ± 0.94 | 14.10 ± 6.38 | Survival | 12.10 ± 6.38 | April 1–April 15, 2022 |
X2/t value | 0.526 | 0.171 | – | 8.841 | 3.349 | – | 3.349 | – |
P value | 0.468 | 0.864 | – | < 0.001 | < 0.001 | – | < 0.001 | – |